- Home
- ALIT vs IMVT Comparison
ALIT vs IMVT Comparison
Compare ALIT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALIT
- IMVT
- Stock Information
- Founded
- ALIT 2017
- IMVT N/A
- Country
- ALIT United States
- IMVT United States
- Employees
- ALIT N/A
- IMVT N/A
- Industry
- ALIT Business Services
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ALIT Consumer Discretionary
- IMVT Health Care
- Exchange
- ALIT Nasdaq
- IMVT Nasdaq
- Market Cap
- ALIT 3.6B
- IMVT 3.6B
- IPO Year
- ALIT N/A
- IMVT N/A
- Fundamental
- Price
- ALIT $6.99
- IMVT $23.59
- Analyst Decision
- ALIT Strong Buy
- IMVT Strong Buy
- Analyst Count
- ALIT 9
- IMVT 11
- Target Price
- ALIT $10.61
- IMVT $46.11
- AVG Volume (30 Days)
- ALIT 5.0M
- IMVT 1.1M
- Earning Date
- ALIT 02-19-2025
- IMVT 02-10-2025
- Dividend Yield
- ALIT 2.29%
- IMVT N/A
- EPS Growth
- ALIT N/A
- IMVT N/A
- EPS
- ALIT N/A
- IMVT N/A
- Revenue
- ALIT $3,358,000,000.00
- IMVT N/A
- Revenue This Year
- ALIT N/A
- IMVT N/A
- Revenue Next Year
- ALIT $3.63
- IMVT N/A
- P/E Ratio
- ALIT N/A
- IMVT N/A
- Revenue Growth
- ALIT 26.91
- IMVT N/A
- 52 Week Low
- ALIT $6.15
- IMVT $22.41
- 52 Week High
- ALIT $10.38
- IMVT $40.36
- Technical
- Relative Strength Index (RSI)
- ALIT 52.19
- IMVT 39.44
- Support Level
- ALIT $6.68
- IMVT $22.41
- Resistance Level
- ALIT $6.88
- IMVT $25.29
- Average True Range (ATR)
- ALIT 0.18
- IMVT 1.22
- MACD
- ALIT 0.04
- IMVT 0.05
- Stochastic Oscillator
- ALIT 99.24
- IMVT 34.91
About ALIT Alight Inc.
Alight Inc is a provider of integrated, cloud-based human capital solutions that empower clients and employees to manage health, wealth and HR needs. Geographically, the company generates a majority of its revenue from the United States.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).